NSR invests $55m in Indian pharma

New Silk Route’s investment in Nectar Lifesciences will be used to fund the expansion of the company’s generic pharmaceutical business.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this